Bouncing Back From A Phase III Flop
Small Pharma’s Road To Recovery
Executive Summary
The passing of a decade always brings with it an inevitable glance in the rear-view mirror to see how far we have come. The pharma industry is no different and it would be remiss to ignore the failings of the industry’s collective R&D engine while also celebrating its successes.
You may also be interested in...
Deal Watch: Conatus Ends NASH Ambitions, Merges With Regenerative Medicine Firm Histogen
Reverse merger takes Histogen public as it seeks mid-stage data for male pattern baldness by end of 2020. AstraZeneca continues divestiture spree, sending five mature hypertension drugs to Atnahs.
Shield Therapeutics Looking At US Options For Feraccru
The UK biotech has revised its business strategy over the past year, and Shield's CEO believes the company's lead product for iron deficiency is now well positioned to compete with current and potential entrants in the therapeutic sector.
Can Fresh INTEREST Breathe New Life Into Faron's Traumakine?
Faron's ARDS drug looked doomed after the INTEREST study earlier this year but the Finnish group claims that a DNA analysis has identified some patients for whom Traumakine treatment could potentially be effective.
| Table |
|---|